Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors

BACKGROUND: Poly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that non-response in some patients may be due to insufficient drug penetration. As a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Breast Cancer Res
Autori principali: Bartelink, Imke H., Prideaux, Brendan, Krings, Gregor, Wilmes, Lisa, Lee, Pei Rong Evelyn, Bo, Pan, Hann, Byron, Coppé, Jean-Philippe, Heditsian, Diane, Swigart-Brown, Lamorna, Jones, Ella F., Magnitsky, Sergey, Keizer, Ron J, de Vries, Niels, Rosing, Hilde, Pawlowska, Nela, Thomas, Scott, Dhawan, Mallika, Aggarwal, Rahul, Munster, Pamela N., Esserman, Laura J., Ruan, Weiming, Wu, Alan H. B., Yee, Douglas, Dartois, Véronique, Savic, Radojka M., Wolf, Denise M., van ’t Veer, Laura
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5594551/
https://ncbi.nlm.nih.gov/pubmed/28893315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-017-0896-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi